Dymicron’s Triadyme-C artificial disc earned the FDA’s investigational device exemption approval, according to a July 10 news release.
The IDE approval opens the door for a U.S. trial of the disc, which is designed for patients with degenerative disc disease. Triadyme-C has bearing surfaces made of Adymite, a proprietary medical grade polycrystalline diamond material made for high-stress load-bearing environments.
“The Triadyme-C represents a remarkable advancement in cervical disc technology,” Richard Guyer, MD, co-primary investigator for clinical trials, said in the release. “Its revolutionary polycrystalline diamond bearing surfaces dramatically reduce wear debris generation, while the tri-lobed design is engineered to closely replicate normal spinal kinematics—two factors that could improve long-term outcomes for patients.”
The first implantations in the U.S. are expected in the fourth quarter.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
